Introduction: Tranexamic acid (TXA) is indicated for the control and prevention of hyperfibrinolysis-induced hemorrhages because it promotes increased clot stability. 11 Since its pre-hospital use is not yet well-defined, the purpose of this article is to evaluate the scientific research on its mechanism of action, indications, and contraindications to supplement the risk-benefit discussion. Methodology: The current study is a literature review, the database of which was taken from the SciELO (Scientific Electronic Library Online) and PubMed platforms.